VERA
Vera Therapeutics, Inc. (VERA) Risks & Opportunities Analysis (2026)
Overall Score
Balance Sheet Strength
VERA retains a very strong liquidity position with a current ratio of 10.9x and cash ratio of 1.01x.
Leverage remains modest with debt-to-equity at 0.18x and debt-to-assets at 0.14x.
Net debt is effectively negligible at -0.07x EBITDA, supporting balance-sheet resilience.
Profitability Cash Flow Risk
Trailing margins and returns remain deeply negative, with ROA at -75.4%, ROE at -84.1%, and ROIC at -85.8%.
Operating cash flow and free cash flow are both negative, with FCF yield at -16.1% and operating cash flow ratio at -7.0x.
Interest coverage is extremely weak at -36.9x, indicating the business is not currently generating earnings to cover financing costs.
Valuation Support
The stock screens as inexpensive on cash-flow-based multiples, with price-to-free-cash-flow at -6.2x and price-to-operating-cash-flow at -6.2x.
Book-value support is present, with price-to-book at 5.17x and tangible book value per share at 5.68.
Negative earnings and cash flow limit the usefulness of traditional earnings-based valuation metrics.
Operational Efficiency
Asset turnover and revenue efficiency remain weak, with revenue per share at 0 and asset turnover at 0.
The cash conversion cycle is highly distorted at 6106.9 days, reflecting unusual working-capital dynamics.
Payables turnover is negative and days payable outstanding is deeply negative, suggesting the operating data is not yet normalized.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Vera Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

